Combination R-BAC Good Against Mantle Cell Lymphoma

Results of a recently published Phase II study by Italian researchers indicate that combination therapy with cytarabine, bendamustine and rituximab can deliver strong response-related outcomes against mantle cell lymphoma.

This combination, also known by the acronym R-BAC, was tested in 40 patients with confirmed mantle cell lymphoma, all of whom were at least 65 years old. Half of the patients were treatment naïve, while the other half had relapsed or refractory MCL following a single regimen of immunochemotherapy.

The primary outcome measure for this study was overall response rate (ORR), which was measure by PET scan. Secondary endpoints were progression-free survival, overall survival and safety. The safety of the dosage was performed in stage one of the study to determine the maximum tolerated dose of cytarabine. Participants then received rituximab on the first day, bendamustine on days two and three, and cytarabine on days two and four every 28 days for between four and six cycles.

Almost all of the participants were staged as having either stage III or stage IV mantle cell lymphoma.

Response Rates

Results indicated that the response rate among the treatment naïve cohort was 100 percent, and this group had a 95 percent rate of progression free survival.

Among the previously treated group the overall response rate was 80 percent, and the progression free survival rate was 70 percent.

The researchers concluded:

On the basis of its remarkable activity, as well as stem-cell mobilizing potential in the first-line setting, R-BAC could be a useful option in the preintensification phase for younger patients with MCL, in whom achieving complete response before transplantation can elicit long-lasting remissions.

Source: Journal of Clinical Oncology

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...